3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Evaluating measurable residual disease in acute myeloid leukemia

      review-article
      1 , , 2 , 3 , 4
      Blood Advances
      American Society of Hematology

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mounting evidence indicates that the presence of measurable (“minimal”) residual disease (MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic detection, is a strong, independent prognostic marker of increased risk of relapse and shorter survival in patients with acute myeloid leukemia (AML) and can be used to refine risk-stratification and treatment response assessment. Because of the association between MRD and relapse risk, it has been postulated that testing for MRD posttreatment may help guide postremission treatment strategies by identifying high-risk patients who might benefit from preemptive treatment. This strategy, which remains to be formally tested, may be particularly attractive with availability of agents that could be used to specifically eradicate MRD. This review examines current methods of MRD detection, challenges to adopting MRD testing in routine clinical practice, and recent recommendations for MRD testing in AML issued by the European LeukemiaNet MRD Working Party. Inclusion of MRD as an end point in future randomized clinical trials will provide the data needed to move toward standardizing MRD assays and may provide a more accurate assessment of therapeutic efficacy than current morphologic measures.

          Related collections

          Author and article information

          Journal
          Blood Adv
          Blood Adv
          bloodoa
          Blood Adv
          Blood Advances
          Blood Advances
          American Society of Hematology (Washington, DC )
          2473-9529
          2473-9537
          12 June 2018
          12 June 2018
          12 June 2018
          : 2
          : 11
          : 1356-1366
          Affiliations
          [1 ]Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;
          [2 ]Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
          [3 ]Division of Hematology, Department of Medicine, University of Washington, Seattle, WA; and
          [4 ]Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
          Article
          PMC5998930 PMC5998930 5998930 2018/016378
          10.1182/bloodadvances.2018016378
          5998930
          29895626
          3f6f9567-a426-456f-87f4-b22d7d4cfcbe
          © 2018 by The American Society of Hematology
          History
          : 17 January 2018
          : 23 April 2018
          Page count
          Pages: 11
          Categories
          5
          20
          25
          Review Article
          Custom metadata
          free

          Comments

          Comment on this article